Trinity Biotech plc (TRIB)

NASDAQ
2.330
+0.030(+1.30%)
After Hours
2.310
-0.020(-0.858%)
- Real-time Data
  • Volume:
    87,059
  • Bid/Ask:
    2.270/2.440
  • Day's Range:
    2.290 - 2.360

TRIB Overview

Prev. Close
2.3
Day's Range
2.29-2.36
Revenue
116.21M
Open
2.32
52 wk Range
1.75-6.8
EPS
-0.07
Volume
87,059
Market Cap
48.7M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
197,752
P/E Ratio
-
Beta
1.67
1-Year Change
14.22%
Shares Outstanding
20,901,702
Next Earnings Date
Oct 27, 2021
What is your sentiment on Trinity Biotech plc?
or
Market is currently closed. Voting is open during market hours.

Trinity Biotech plc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellSellStrong Sell
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Sell
SummarySellStrong SellStrong SellStrong SellStrong Sell

Trinity Biotech plc Company Profile

Trinity Biotech plc Company Profile

Employees
543

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech's blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

Read More
  • it's coming waiting on FDA APPROVAL
    0
    • this will go 12 in week
      2
      • To the moon 27$ here we come
        1
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.